Fact.MR – A Market Research and Competitive Intelligence Provider: The global Lewy Body Dementia treatment market is projected to surpass a valuation of US$ 3,500.5 Mn between 2018 and 2028, according to newly released data by Fact.MR.
Cholinesterase Inhibitors to Remain Most-Preferred Drug Type for Lewy Body Dementia Treatment with Revenue Surpassing US$ 2.1 Bn through 2028
In a recent analysis on Lewy Body Dementia treatment market, Fact.MR divulges current trends and opportunities prevailing in the market to help readers understand the market dynamics. Drivers, restraints, and growth strategies adopted by key market players are mentioned in the report. The report also covers developments affecting trajectory across various in segments of the market including drug type, indication, and distribution channels across seven regions.
Fact.MR – A Market Research and Competitive Intelligence Provider: The global Lewy Body Dementia treatment market is projected to surpass a valuation of US$ 3,500.5 Mn between 2018 and 2028, according to newly released data by Fact.MR.
As per a report on the clinical prevalence of Lewy Body Dementia published by the U.S. National Library of Medicine, National Institutes of Health, patients with dementia with Lewy bodies (DLB) comprise 4.6% of all dementia cases.
Dementia with Lewy Bodies (DLB) is a common cause of dementia in the geriatric population, which is characterized by symptoms such as visual hallucinations, fluctuations in cognition, spontaneous parkinsonism, and sleep behavior disorder.
Request a report sample to gain comprehensive insights at
https://www.factmr.com/connectus/sample?flag=S&rep_id=1154
With increasing geriatric population across the globe, need for Lewy Body Dementia treatment is projected to rise at a steady pace over the assessment period. Besides this, government-led initiatives to spread awareness regarding dementia are expected to provide impetus to the sales.
For instance, in the U.S., the National Alzheimer’s Project Act (NAPA) was passed to accelerate research on Alzheimer’s diseases and various types of dementia to provide better treatment and clinical care services to patients and their families.
Increasing prevalence of dementia is compelling manufacturers to invest in research and development to launch effective and easily accessible treatment medications. Inadequate availability of generic dementia treatment drugs in emerging economies is expected to open lucrative opportunities for key market players in the forthcoming years.
As per Fact.MR’s regional survey, North America will continue its dominance in the global market. Growth is attributed to increasing awareness of dementia and age-related health disorders in the region, along with strong presence of key market players and medical research institutes.
“Ongoing clinical trials to enhance the efficacy of currently available dementia treatment medications, coupled with collaborations among medical research institutes and pharmaceutical companies to launch novel drugs for dementia treatment, will continue augmenting growth in the market over the assessment period,” says a Fact.MR analyst.
Key Takeaways:
- The cholinesterase inhibitors segment is projected to surpass a valuation of US$2 2.1 Bn over the forecast period.
- The U.S. market is expected to remain the most lucrative due to the presence of well-established healthcare infrastructure in the region.
- East Asia is anticipated to witness high demand for Lewy Body Dementia treatment, especially from India and China.
- Based on indication, Dementia with Lewy Bodies (DLB) will dominate the segment over the forecast period
- Brazil is expected to spearhead the growth of Latin America market on the back of increasing research and development activities for the treatment in country
Growth Drivers:
- Favorable healthcare reimbursement policies encompassing treatment for dementia and Alzheimer's patients in various countries will propel sales of the treatment.
- Wide availability and easy delivery of dementia treatment medications through online pharmacies are expected to bolster demand.
Restraints:
- High costs associated with Lewy Body Dementia treatment medication might hamper the sales.
- Adverse side effects of long-term use of dementia medication, such as nausea, insomnia, diarrhea, and vomiting are likely limit the growth in the market.
To gain in-depth insights on Lewy Body Dementia Treatment Market, request methodology at
https://www.factmr.com/connectus/sample?flag=RM&rep_id=1154
Competitive Landscape
As per Fact.MR, players operating in the global market are investing in research and development to expand their product portfolios by adding medication specifically tailored for dementia patients.
Apart from this, key players are expanding their distribution network by collaborating with hospitals, clinics, and research institutes to gain a competitive edge in the market.
For instance,
- Sumitomo Dainippon Pharma Co., Ltd, a Japan-based pharmaceutical company, entered into a joint research agreement with Aikomi, Ltd. to develop medical devices to treat behavioral and psychological symptoms of dementia.
- In 2018, IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for common and rare neurodegenerative diseases, announced the results for its lead compound series (IB1000s) for the treatment of dementia, including positive clinical results from compassionate-use studies in patients with Lewy Body Dementia and Fronto-Temporal Dementia, and from pre-clinical studies in Alzheimer’s Disease.
Key Players in the Lewy Body Dementia Treatment Market Include:
- BioArctic AB
- Sumitomo Dainippon Pharma Co., Ltd.
- Jazz Pharmaceuticals, Inc.
- Noven Pharmaceuticals, Inc.
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Bayer AG
- Mylan NV
- Sanofi AG
- Teva Pharmaceuticals
- GlaxoSmithKline
- Eisai Co., Ltd.
- Takeda Pharmaceutical Company Ltd.
- Allergan Plc.
- Janssen Pharmaceuticals, Inc.
- Bausch Health Companies Inc.
- Mallinckrodt Pharmaceuticals
More Valuable Insights on Lewy Body Dementia Treatment Market
Fact.MR sheds deeper insights on the Lewy Body Dementia treatment market, presenting historical demand data (2013-2017) and forecast statistics for the period from 2018-2028. The study offers exhaustive analysis on the global Lewy Body Dementia treatment market with a detailed segmentation on the basis of:
Drug Type:
- Cholinesterase Inhibitors
- Antipsychotic Drugs
- Carbidopa-Levodopa
- Antidepressants
- Benzodiazepine
- Modafinil
Indication:
- Dementia with Lewy Bodies (DLB)
- Parkinson’s Disease
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Regions:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- MEA
Key Questions Covered in the Lewy Body Dementia Treatment Market Report
- The report offers insight into the Lewy Body Dementia treatment market demand outlook for 2018-2028.
- The market study also highlights projected sales growth for Lewy Body Dementia treatment market between 2018 and 2028.
- Lewy Body Dementia treatment market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry.
- Lewy Body Dementia treatment market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others.
Explore Fact.MR’s Coverage on the Healthcare Domain –
Benzodiazepine Drugs Market- Benzodiazepine drugs are a single panacea for a variety of illnesses, including anxiety, insomnia, and seizures, fueling sales through a variety of applications. As people become more aware of the negative effects of psychoactive substances, they are more likely to use benzodiazepine medicines, which are relatively harmless. Fact.MR conducted a thorough study on the significance of these critical dynamics. Demand for benzodiazepine drugs will remain high—albeit for generics—driving a large number of sales while contributing only significantly to market value.
Rare Neurodegenerative Disease Treatment Market- Market participants are increasing their investments in medication development for the treatment of neurodegenerative diseases, and patients are becoming more aware of the various therapeutic choices available. In the long run, the rise in medical tourism and investments in modernizing healthcare infrastructure across Asia Pacific's developing countries are projected to benefit the rare neurodegenerative disease treatment market. Long-term growth will be aided by advances in medical technology for the diagnosis and treatment of various ailments.
Rare Neurological Disease Treatment Market- The incidence of rare diseases, the evolving trend of orphan drugs, and rising healthcare spending have all contributed to a significant increase in overall sales of rare neurological treatments during the previous decade. Furthermore, the rare neurological disease treatment market is expected to be the most attractive market among the rare disease treatment markets. Rapid advancements in healthcare, as well as major socioeconomic shifts that result in altered lifestyles, are allowing manufacturers to increase their footprint in the rare neurological disease treatment market.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR